We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Assessment of Biotherapeutics Quality Attributes Leveraging a Novel Fragmentation Technique
Webinar

Assessment of Biotherapeutics Quality Attributes Leveraging a Novel Fragmentation Technique

Assessment of Biotherapeutics Quality Attributes Leveraging a Novel Fragmentation Technique
Webinar

Assessment of Biotherapeutics Quality Attributes Leveraging a Novel Fragmentation Technique

Armelle Martelet PhD
Armelle Martelet PhD
Deputy Head of Structural Analysis Lab, BioAnalytics, Sanofi R&D, Sanofi

As the number of biotherapeutic candidates in development is increasing, the requirements of analytical tools to improve insights on the molecules early in the process are also rising. To understand product quality attributes (PQAs) fully, identification, localization and relative quantification are key. Mass spectrometry (MS) plays an important role, with peptide mapping being the gold standard to assess post-translational modifications (PTM). However, traditionally used collision-induced dissociation (CID) has several limitations in PTM identification and localization.

The novel fragmentation technique, electron activated dissociation (EAD) of the ZenoTOF 7600 system (SCIEX), was employed for peptide mapping of a multispecific monoclonal antibody (mAb) as well as IgG1 and IgG4 mAb samples. A specific focus was put on assessing challenging PTMs, such as glycosylations, amino acid isomers and the localization of a sulfation on a singly charged peptide.


Attend this webinar to:

  • Gain insight on the characterization of challenging PTMs such as glycosylations and amino acid isomers
  • Learn about the fragments providing positional information that could be detected with EAD
  • Discover how you can characterize biotherapeutics with the novel ZenoTOF 7600 system
Advertisement